The drug didn’t make blood sugar or insulin levels better, so its benefits must come from somewhere else — likely directly on muscle energy production.
Scientific Claim
In obese adults with reduced GH, tesamorelin treatment did not significantly alter fasting glucose, insulin, or insulin resistance after 12 months, indicating its metabolic effects are not mediated through improved glucose metabolism.
Original Statement
“Treatment with tesamorelin did not affect fasting glucose, 2-hour glucose with an OGTT, fasting insulin, or homeostasis model assessment of insulin resistance (all P > .10).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
This is a direct, measured outcome with non-significant P-values from an RCT. Definitive language is appropriate for reporting the absence of an effect.
Evidence from Studies
Supporting (0)
Contradicting (1)
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
This study looked at how well muscles recover energy after exercise, not at blood sugar or insulin levels, so it doesn’t tell us whether tesamorelin affects glucose metabolism as the claim says.